Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a look a top executive compensation; BioMarin preps for Roctavian’s EU debut; Argenx eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and J&J’s Gorsky offers leadership lessons.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 1 July 2022, including: a look a top executive compensation; BioMarin Pharmaceutical Inc. preps for Roctavian’s EU debut; argenx N.V. eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and Johnson & Johnson’s Gorsky offers leadership lessons.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again" - Scrip, 28 Jun, 2022.)
(Also see "BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut" - Scrip, 24 Jun, 2022.)
(Also see "Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up" - Scrip, 24 Jun, 2022.)
(Also see "Are Market Conditions Setting Up A Biopharma M&A Wave?" - Scrip, 23 Jun, 2022.)
(Also see "J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple" - Scrip, 30 Jun, 2022.)